Levora
NDC 54868-4607
Product Information
Levora is a ANDA-approved product labeled by Physicians Total Care, Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a white product. This product entry covers the primary NDC 54868-4607 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
ORANGE (C48331 - PEACH)
1530;WATSON
WATSON;P1
Code Structure Chart
Product Details
What is NDC 54868-4607?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- LEVONORGESTREL (UNII: 5W7SIA7YZW)
- LEVONORGESTREL (UNII: 5W7SIA7YZW) (Active Moiety)
- ETHINYL ESTRADIOL (UNII: 423D2T571U)
- ETHINYL ESTRADIOL (UNII: 423D2T571U) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)
- LACTOSE (UNII: J2B2A4N98G)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- POVIDONE (UNII: FZ989GH94E)
- ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)
- FD&C YELLOW NO. 6 (UNII: H77VEI93A8)
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 238019 - levonorgestrel 0.15 MG / ethinyl estradiol 0.03 MG Oral Tablet
- RxCUI: 238019 - ethinyl estradiol 0.03 MG / levonorgestrel 0.15 MG Oral Tablet
- RxCUI: 748797 - inert 1 MG Oral Tablet
- RxCUI: 748797 - inert ingredients 1 MG Oral Tablet
- RxCUI: 748878 - {21 (ethinyl estradiol 0.03 MG / levonorgestrel 0.15 MG Oral Tablet) / 7 (inert ingredients 1 MG Oral Tablet) } Pack
* Please review the full disclaimer at the bottom of this page.